Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial
Burgos RA, Hancke JL, Bertoglio JC, Aguirre V, Arriagada S, Calvo M, Caceres DD
Published in Clinical Rheumatology
Methodology
Prospective, randomized, double-blind, placebo-controlled trial of an Andrographis paniculata extract standardized to 30% andrographolides, three times daily for 14 weeks after a 2-week washout, in patients with active rheumatoid arthritis.
Key Findings
The primary endpoint, joint pain intensity on a visual analog scale, did not differ significantly from placebo. Within-group improvements were seen in tender and swollen joint counts, HAQ and SF-36, alongside reductions in rheumatoid factor, IgA and C4.
Conclusions
Andrographis paniculata could be a useful complement in rheumatoid arthritis, but a larger and longer trial is needed to confirm the findings.
Limitations
The primary pain endpoint was negative; several reported benefits are within-group rather than between-group comparisons, and the sample of 60 patients is small.
Supplements Studied
The intensity of joint pain decreased in the active vs placebo group at the end of treatment, although these differences were not statistically significant.
Outcomes Measured
Moreover, it was associated to a reduction of rheumatoid factor, IgA, and C4.
The intensity of joint pain decreased in the active vs placebo group at the end of treatment, although these differences were not statistically significant.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Universidad Austral de Chile; extract supplied by the manufacturer
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.